The DOI matches its Crossref record; 248 of the 248 references it cites were found in a registry or an index.
PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
Open accessAbstract
The Poly (ADP-ribose) polymerase (PARP) family has many essential functions in cellular processes, including the regulation of transcription, apoptosis and the DNA damage response. PARP1 possesses Poly (ADP-ribose) activity and when activated by DNA damage, adds branched PAR chains to facilitate the recruitment of other repair proteins to promote the repair of DNA single-strand breaks. PARP inhibitors (PARPi) were the first approved cancer drugs that specifically targeted the DNA damage response in BRCA1/2 mutated breast and ovarian cancers. Since then, there has been significant advances in our understanding of the mechanisms behind sensitization of tumors to PARP inhibitors and expansion of the use of PARPi to treat several other cancer types. Here, we review the recent advances in the proposed mechanisms of action of PARPi, biomarkers of the tumor response to PARPi, clinical advances in PARPi therapy, including the potential of combination therapies and mechanisms of tumor resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–248 of 248
Vidotto, T., Nersesian, S., Graham, C. H., Siemens, D. R., & Koti, M. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0619-8 · Cited by 83
Regulators of homologous recombination repair as novel targets for cancer treatment
Krajewska, M., Fehrmann, R. S. N., de Vries, E. G. E., & van Vugt, M. A. T. M. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00096 · Cited by 82
Hurley, R. M., Hendrickson, A. E. W., Visscher, D. W., Ansell, P. J., Harrell, M. I., Wagner, J. M., Negron, V. C., Goergen, K. M., Maurer, M. J., Oberg, A. L., et al. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.01.015 · Cited by 81
The PARP3- and ATM-dependent phosphorylation of APLF facilitates DNA double-strand break repair
Fenton, A. L., Shirodkar, P., Macrae, C. J., Meng, L., & Koch, C. A. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt134 · Cited by 80
Choi, Y. E., Pan, Y., Park, E., Konstantinopoulos, P. A., De, S., D’Andrea, A. D., & Chowdhury, D. (2014) · eLife · doi:10.7554/elife.02445 · Cited by 80
Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer
Dockery, L., Gunderson, C., & Moore, K. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s114714 · Cited by 78
NADP+ is an endogenous PARP inhibitor in DNA damage response and tumor suppression
Bian, C., Zhang, C., Luo, T., Vyas, A., Chen, S.-H., Liu, C., Kassab, M. A., Yang, Y., Kong, M., & Yu, X. (2019) · Nature Communications · doi:10.1038/s41467-019-08530-5 · Cited by 67
Gaymes, T. J., Mohamedali, A. M., Patterson, M., Matto, N., Smith, A., Kulasekararaj, A. G., Chelliah, R., Curtin, N. J., Farzaneh, F., Shall, S., et al. (2013) · Haematologica · doi:10.3324/haematol.2012.079251 · Cited by 64
Smith, M. R., Sandhu, S. K., Kelly, W. K., Scher, H. I., Efstathiou, E., Lara, P. N., Yu, E. Y., George, D. J., Chi, K. N., Summa, J. M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.7_suppl.202 · Cited by 63
Bolderson, E., Burgess, J. T., Li, J., Gandhi, N. S., Boucher, D., Croft, L. V., Beard, S., Plowman, J., Suraweera, A., Adams, M. N., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13167-5 · Cited by 62
Self-citationClements, K. E., Schleicher, E. M., Thakar, T., Hale, A., Dhoonmoon, A., Tolman, N. J., Sharma, A., Liang, X., Kawasawa, Y. I., Nicolae, C. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19961-w · Cited by 59
Fu, K., Sun, X., Wier, E. M., Hodgson, A., Liu, Y., Sears, C. L., & Wan, F. (2016) · eLife · doi:10.7554/elife.15018 · Cited by 55
Methylation and ovarian cancer: Can DNA methylation be of diagnostic use? (Review)
Hentze, J. L., Høgdall, C. K., & Høgdall, E. V. S. (2019) · Molecular and Clinical Oncology · doi:10.3892/mco.2019.1800 · Cited by 55
Poly(ADP-ribosyl)ation of p53 induces gene-specific transcriptional repression of MTA1
Lee, M., Na, H., Kim, E.-J., Lee, M.-O., & Lee, M.-O. (2012) · Oncogene · doi:10.1038/onc.2012.2 · Cited by 48
BRCA Mutation Frequency and Penetrance: New Data, Old Debate
Offit, K. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj500 · Cited by 48
Gornstein, E. L., Sandefur, S., Chung, J., Gay, L. M., Holmes, O., Erlich, R., Soman, S., Martin, L.-A., Rose, A. V., Stephens, P. J., et al. (2017) · Clinical Breast Cancer · doi:10.1016/j.clbc.2017.12.010 · Cited by 48
Sam68 Is Required for DNA Damage Responses via Regulating Poly(ADP-ribosyl)ation
Sun, X., Fu, K., Hodgson, A., Wier, E. M., Wen, M. G., Kamenyeva, O., Xia, X., Koo, L. Y., & Wan, F. (2016) · PLoS Biology · doi:10.1371/journal.pbio.1002543 · Cited by 46
Mechanisms of resistance to alkylating agents
Damia, G. L. M., & D’Incalci, M. (1998) · Cytotechnology · doi:10.1023/a:1008060720608 · Cited by 45
Y-box-binding protein 1 as a non-canonical factor of base excision repair
Alemasova, E. E., Moor, N. A., Naumenko, K. N., Kutuzov, M. M., Sukhanova, M. V., Pestryakov, P. E., & Lavrik, O. I. (2016) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2016.08.012 · Cited by 44
Pachkowski, B. F., Tano, K., Afonin, V., Elder, R. H., Takeda, S., Watanabe, M., Swenberg, J. A., & Nakamura, J. (2009) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2009.09.006 · Cited by 42
Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance
Wang, W., & Figg, W. D. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.7.6409 · Cited by 42
Vos, S., van Diest, P. J., & Moelans, C. B. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.05.008 · Cited by 42
Criscuolo, D., Morra, F., Giannella, R., Cerrato, A., & Celetti, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20123100 · Cited by 42
Majuelos‐Melguizo, J., Rodríguez, M. I., López-Jiménez, L., Rodríguez-Vargas, J. M., Martí, J. M., Serrano, S., Gavard, J., de Almodóvar, J. M. R., & Oliver, F. J. (2014) · Oncotarget · doi:10.18632/oncotarget.2993 · Cited by 41
Xue, X., Raynard, S. J., Busygina, V., Singh, A. K., & Sung, P. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.465609 · Cited by 41
Role of Biomarkers in the Development of PARP Inhibitors
Ganguly, B., Dolfi, S. C., Rodríguez-Rodríguez, L., Ganesan, S., & Hirshfield, K. M. (2016) · Biomarkers in Cancer · doi:10.4137/bic.s36679 · Cited by 41
The ATP-bound conformation of the Mre11–Rad50 complex is essential for Tel1/ATM activation
Cassani, C., Vertemara, J., Bassani, M., Marsella, A., Tisi, R., Zampella, G., & Longhese, M. P. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz038 · Cited by 41
Alemasova, E. E., Naumenko, K. N., Kurgina, T. A., Anarbaev, R. O., & Lavrik, O. I. (2018) · Oncotarget · doi:10.18632/oncotarget.25158 · Cited by 36
Han, Y., Chen, M., Wang, H.-L., Hsu, J. L., Li, C.-W., Chu, Y., Liu, C., Nie, L., Chan, L.-C., Yam, C., et al. (2019) · Europe PMC (PubMed Central) · Cited by 33
The DNA damage response in immunotherapy and radiation
Samstein, R. M., & Riaz, N. (2018) · Advances in Radiation Oncology · doi:10.1016/j.adro.2018.08.017 · Cited by 32
Luo, J., Dai, X., Hu, H., Chen, J., Zhao, L., Yang, C., Sun, J., Zhang, L., Wang, Q., Xu, S., et al. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-03097-6 · Cited by 30
Bu, H., Chen, J., Li, Q., Hou, J., Wei, Y., Yang, X., Ma, Y., He, H., Zhang, Y., & Kong, B. (2019) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.14090 · Cited by 28
Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms
Pratz, K. W., Koh, B. D., Patel, A. G., Flatten, K. S., Poh, W., Herman, J. G., Dilley, R. L., Harrell, M. I., Smith, B. D., Karp, J. E., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2351 · Cited by 26
Singh, A. A., Mandoli, A., Prange, K. H. M., Laakso, M., & Martens, J. H. A. (2016) · Oncotarget · doi:10.18632/oncotarget.14150 · Cited by 26
Targeting ADP-ribosylation by PARP inhibitors in acute myeloid leukaemia and related disorders
Faraoni, I., Giansanti, M., Voso, M. T., Lo‐Coco, F., & Graziani, G. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.04.019 · Cited by 24
PARP inhibition causes premature loss of cohesion in cancer cells
Kukolj, E., Kaufmann, T., Dick, A. E., Zeillinger, R., Gerlich, D. W., & Slade, D. (2017) · Oncotarget · doi:10.18632/oncotarget.21879 · Cited by 23
Olaparib tablets for the treatment of germ line BRCA-mutated metastatic breast cancer
Le, D., & Gelmon, K. A. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1513321 · Cited by 22
Han, H., Dieras, V. C., Robson, M. E., Palácová, M., Marcom, P. K., Jager, A., Bondarenko, I., Citrin, D. L., Campone, M., Telli, M. L., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.sabcs16-s2-05 · Cited by 20
Hurvitz, S. A., Quek, R. G. W., Turner, N. C., Telli, M. L., Rugo, H. S., Mailliez, A., Ettl, J., Grischke, E., Mina, L. A., Balmañà, J., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.09.003 · Cited by 19
Triple-negative breast cancer frequency and type of BRCA mutation: Clues from Sardinia
Palomba, G., Budroni, M., Olmeo, N. A., Atzori, F., Ionta, M. T., Pisano, M., Tanda, F., Cossu, A., & Palmieri, G. (2014) · Oncology Letters · doi:10.3892/ol.2014.1834 · Cited by 18
In cellulophosphorylation of XRCC4 Ser320 by DNA-PK induced by DNA damage
Sharma, M. K., Imamichi, S., Fukuchi, M., Samarth, R. M., Tomita, M., & Matsumoto, Y. (2015) · Journal of Radiation Research · doi:10.1093/jrr/rrv086 · Cited by 17
Aggressive leukemia driven by MLL-AF9
Stavropoulou, V., Peters, A. H. F. M., & Schwaller, J. (2016) · Molecular & Cellular Oncology · doi:10.1080/23723556.2016.1241854 · Cited by 17
Fu, K., Sun, X., Wier, E. M., Hodgson, A., Hobbs, R. P., & Wan, F. (2016) · eLife · doi:10.7554/elife.21957 · Cited by 17
Superfast DNA replication causes damage in cancer cells
Quinet, A., & Vindigni, A. (2018) · Nature · doi:10.1038/d41586-018-05501-6 · Cited by 16
Recombination: Homologous recombination branches out
Hiom, K. J. (2001) · Current Biology · doi:10.1016/s0960-9822(01)00138-5 · Cited by 15
Assembling a protective shield
Greenberg, R. A. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0152-x · Cited by 14
Mamdani, H. M., Chen, J. Y., Kim, S., Ibrahim, Y., Asad, M., Nieva, J. J., Feldman, R. A., Naqash, A. R., Liu, S. V., Ma, P. C., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.9100 · Cited by 12
Chovanec, M., Taza, F., Kalra, M., Hahn, N. M., Nephew, K. P., Spinella, M. J., & Albany, C. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0546-x · Cited by 11
Cited by
Huang, R., & Zhou, P.-K. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00648-7 · Cited by 907
Molecular targeted therapy for anticancer treatment
Min, H.-Y., & Lee, H.-Y. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00864-3 · Cited by 569
Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer
Labrie, M., Brugge, J. S., Mills, G. B., & Zervantonakis, I. K. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00454-5 · Cited by 369
Advances in PET imaging of cancer
Schwenck, J., Sonanini, D., Cotton, J. M., Rammensee, H.-G., la Fougère, C., Zender, L., & Pichler, B. J. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00576-4 · Cited by 312
Saturation genome editing maps the functional spectrum of pathogenic VHL alleles
Buckley, M., Terwagne, C., Ganner, A., Cubitt, L., Brewer, R., Kim, D.-K., Kajba, C. M., Forrester, N., Dace, P., De Jonghe, J., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01800-z · Cited by 62
Metadata
- Authors
- Rose, M., Burgess, J. T., O’Byrne, K., Richard, D. J., & Bolderson, E.
- Venue
- Frontiers in Cell and Developmental Biology
- Publisher
- Frontiers Media SA
- Published
- 2020-09-09
- Volume
- 8
- Pages
- 564601-564601
- ISSN
- 2296-634X (ISSN-L)
- OpenAlex
- W3084114043
- Cited by
- 719
- References
- 248
- FWCI
- 26.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.